Articles Referencing NVGN

SeekingAlpha

Will MannKind's Afrezza Succeed Where Pfizer's Exubera Failed?

Rockford Coscia submits: This December, Afrezza, MannKind's ( MNKD ) inhalable insulin therapy for prandial (meal-time) management of blood glucose in diabetics, faces FDA decision.... Read >>